Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 9/20 | 1.00 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.65 |
| ▸ | DDO | Q99489 | 4/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | PDE6A | P16499 | 1/20 | 0.42 |
| ▸ | PDE6G | P18545 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE6B | P35913 | 1/20 | 0.42 |
| ▸ | PDE6C | P51160 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663285 | 0.79 | ATAD2 (1.00) | DAOATAD2DDOPARP1HRH4 | |
| SCHEMBL24970980 | 0.79 | DAO (0.65) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL31143069 | 0.79 | DAO (0.65) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL1472999 | 0.77 | DAO (0.62) | DAOATAD2HRH4PDE5A | |
| SCHEMBL17601429 | 0.77 | DAO (0.62) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL16463537 | 0.77 | DAO (0.62) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL24390514 | 0.76 | ATAD2 (0.66) | DAOATAD2DDOPARP1HRH4 | |
| SCHEMBL21551043 | 0.75 | ATAD2 (0.64) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL24312059 | 0.75 | ATAD2 (0.64) | DAOATAD2PARP1HRH4PDE2A | |
| SCHEMBL22016868 | 0.75 | ATAD2 (0.64) | DAOATAD2PARP1HRH4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024260023-A1 | CYCLIC Α-HYDROXYIMIDE COMPOUND AND USE THEREOF | 北京英飞智药科技有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-119176777-A | Cyclic alpha-hydroxyimide compound and application thereof | 北京英飞智药科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468669-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-11 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339482-B2 | Methods to treat dysregulated blood glucose disorders | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-06-04 | — | — | US | disclosed |
| WO-2010058314-A1 | HYDROXYQUINOLIN-2(1H)-ONES AND DERIVATIVES THEREOF | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150836-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885ATAD2 3893/4885DDO 2128/4885 |
| US-20160228515-A1 | METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS | SLC2A4, SLC2A2, SLC2A3 | DAO 3050/4885ATAD2 3893/4885DDO 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.